http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106608912-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505 |
| filingDate | 2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106608912-B |
| titleOfInvention | A kind of EPO simulation peptide derivant and its preparation method and application that aliphatic dicarboxylic acid is coupled |
| abstract | The present invention relates to a kind of Erythropoietin mimetic peptide derivatives of aliphatic dicarboxylic acid coupling, and the simulation peptide derivant is sequence monomeric peptide as shown in SEQ ID NO:1: SEQ ID NO:1 GGLYAC6HMGPITX 1 VC15QPLRX 2 K；Wherein, X 2 For 3- (1- naphthalene)-l-Alanine (Nal), X 4 For sarcosine (Sar), X 1 For K or R, X 3 For K or R, X 1 And X 3 Side-chain amino group is through straight chain fatty dicarboxylic acids such as malonic acid, maleic acid, succinic acid, the connections such as glutaric acid circlewise, N-terminal acetylation.The present invention also provides the preparation method of the simulation peptide derivant and its officinal salts.The present invention still further provides the pharmaceutical composition containing above-mentioned simulation peptide derivant or its officinal salt.Erythropoietin mimetic peptide derivative of the invention and its officinal salt can stimulate RBC acceptor garland rate, and significantly extend the half-life period of drug in vivo. |
| priorityDate | 2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.